(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
...
Nevro (NVRO) said Wednesday the US Food and Drug Administration has approved its Senza HFX iQ spinal cord stimulation system. The company said the...
Nevro (NVRO) shares were down 4.9% around midday Wednesday after Jefferies initiated coverage with an underperform rating and a $31 price target. Trading...
Investors continue to be optimistic about Nevro (NVRO), owing to its strength in the global SCS...
| Address | 1800 Bridge Parkway Redwood City, California 94065 |
| Phone | +1.650.251.0005 |
| Number of Employees | 804 |
| Recent SEC Filing | 11/15/2022 4 |
| Chairman, President & Chief Executive Officer | D. Keith Grossman |
| Chief Financial Officer | Roderick H. MacLeod |
| Chief Medical Officer | David Caraway |
| Vice President-Technical Operations | Christopher Christoforou |
| Price Open | $44.17 |
| Previous Close | $45.19 |
| 52 Week Range | $34.70 - 98.12 |
| Market Capitalization | $1.5 B |
| Shares Outstanding | 35.4 M |
| Sector | Health Technology |
| Industry | Medical Specialties | Next Earnings Announcement | 02/22/2023 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$2.33 |
| Beta vs. S&P 500 | N/A |
| Revenue | $387.3 M |
| Net Profit Margin | -2.01% |
| Return on Equity | -2.89% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
